Conceptual Entity – Page 3

Ocaliva (Obeticholic Acid) Linked to Increased Risk of Liver Failure in PBC Patients Without Cirrhosis

4 months ago talkbio0Tagged Cautionary Warning, Injury of liver, Liver Cirrhosis, Liver Failure, obeticholic acid, Ocaliva, Primary Biliary Cholangitis, United States Food and Drug Administration

Ocaliva, obeticholic acid, primary biliary cholangitis (PBC), liver failure, liver injury, cirrhosis, FDA warning.

Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment

5 months ago talkbio0Tagged Anemia, Sickle Cell, Clinical Practice Guideline, gene therapy, Hematological Disease, Hematology (discipline), Improvement, Quality

Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement

Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced

5 months ago talkbio0Tagged asset, cull, Drug Industry, Incyte, News [Publication Type]

Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry

UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes

6 months ago talkbio0Tagged agonists, Cautionary Warning, Esthetics (discipline), Glucagon-Like Peptide 1, health secretary, MHRA, MISUSE, UK, Weight Loss, Weight-Loss Agents

GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings

FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks

6 months ago talkbio0Tagged Autologous (qualifier value), Automobiles, BCMA, BCMA-directed, boxed, CAR-T therapy, Cautionary Warning, CD19-directed, Neoplasm Metastasis, T-cell immunotherapies, T-Lymphocyte, United States Food and Drug Administration

CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

6 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition

WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny

6 months ago talkbio0Tagged AppTec, asset, Biological Factors, BIOSECURE, Industry, Relations, Sales - occupational activity, U.S.-China, WuXi

WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations

Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows

7 months ago talkbio0Tagged Benchtop DNA Sequencer, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, MiSeq, Push-Button, Workflow

Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

7 months ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment

7 months ago talkbio0Tagged apitegromab, Clinical Trials, GDF8 protein, human, Improvement, Motor function (observable entity), Phase 3, Psychological inhibition, Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition